Lilly's move to hide Phase 1 pipeline draws mixed reviews

As its world-leading GLP-1 earns more than any other medicine — and its market cap eclipses all other healthcare companies — Eli Lilly has decided to stop disclosing its Phase 1 pipeline. Lilly